Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Avidity Biosciences Introduces Breakthrough Del-zota for the Treatment of Duchenne Muscular Dystrophy
Avidity Biosciences has introduced delpacibart zotadirsen (del-zota) as the first and only investigational therapy to receive FDA Breakthrough Therapy designation for the treatment of Duchenne muscular dystrophy....
Revolution Medicines Introduces Breakthrough Elironrasib for the Treatment of KRAS G12C-Mutated Non-Small Cell Lung Cancer
Revolution Medicines has introduced elironrasib as the first and only investigational therapy to receive FDA Breakthrough Therapy designation for the treatment of adult patients with KRAS G12C-mutated...
Praxis Precision Medicines Introduces Breakthrough Relutrigine Therapy
Praxis Precision Medicines has introduced relutrigine as a first-in-class investigational therapy to receive U.S. FDA Breakthrough Therapy designation for the treatment of seizures associated...
Daiichi Sankyo Introduces ENHERTU® Plus Pertuzumab as First-Line Treatment for HER2 Positive Metastatic Breast Cancer
Daiichi Sankyo has introduced ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab as the first-line treatment for adults with unresectable or metastatic HER2 positive breast cancer...
Dyne Therapeutics Introduces Breakthrough DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Dyne Therapeutics has introduced DYNE-101 as the first and only investigational therapy to receive FDA Breakthrough Therapy designation for the treatment of myotonic dystrophy type 1 (DM1)....
Cellectar Introduces Breakthrough Radiotherapeutic Iopofosine I-131 for the Treatment of Waldenstrom’s Macroglobulinemia
Cellectar has introduced iopofosine I-131 as the first and only investigational radiotherapeutic agent to receive FDA Breakthrough Therapy designation for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia (r/r WM)....
Novartis Unveils First and Only Fabhalta® (iptacopan) for the Treatment of C3 Glomerulopathy (C3G)
Novartis has introduced Fabhalta® (iptacopan) as the first and only FDA-approved treatment for adults with C3 glomerulopathy (C3G), a rare and progressive kidney disease that often leads to kidney failure....
Innovent Biologics Launches First-in-Class IGF-1R Monoclonal Antibody for Thyroid Eye Disease
Innovent Biologics has introduced SYCUME® (teprotumumab N01) as a groundbreaking IGF-1R-targeting antibody for thyroid eye disease (TED), marking China’s first and the world’s second approved therapy of its kind....
uniQure Introduces Breakthrough Gene Therapy AMT-130 for the Treatment of Huntington’s Disease
uniQure has introduced AMT-130 as the first and only investigational gene therapy to receive FDA Breakthrough Therapy designation for the treatment of Huntington’s disease....
BrainChild Bio Introduces Breakthrough B7-H3 CAR T-Cell Therapy for Diffuse Intrinsic Pontine Glioma
BrainChild Bio has introduced BCB-276, an investigational B7-H3 targeting CAR T-cell therapy for the treatment of diffuse intrinsic pontine glioma (DIPG), a rare and fatal paediatric brain tumour....
